Tradestie Institutional Equity Comparison Engine

LCTX vs OABI โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

OABI Overall Edge

OABI Captures Institutional Edge (3โ€“1 Pillars ยท 5โ€“5 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to OmniAb, Inc. Common Stock (OABI) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while LCTX counters with relative strength in Valuation. Fundamentally, LCTX trades at 30.7x Forward P/E with -280.3% operating margin (-61.0% YoY revenue) versus OABI at N/M Forward P/E and -92.9% operating margin (+78.3% YoY). In options structure, LCTX sits in BREAKDOWN (<1st %ile IV; Dealer Gamma Walls on Pro) against OABI sits in CONSOLIDATION (14th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner LCTX
LCTX 30.7x vs OABI N/M Fwd P/E
Growth & Margin Winner OABI
Op Margin -280.3% vs -92.9% ยท YoY -61.0% vs +78.3%
Momentum & Technical Winner OABI
1Y -54.9% vs +182.4% ยท 52W Pos 0% vs 81%
Options & Structure Winner OABI
BREAKDOWN (<1st %ile IV) vs CONSOLIDATION (14th %ile IV)
LCTX NYSE American
Lineage Cell Therapeutics, Inc.
Biological Products, (No Disgnostic Substances)
$0.77
-5.87% 1D
Market Cap $207.4M
1M Return -21.63%
1Y Return -54.86%
Forward P/E 30.7x
Unified AI Score
54.9 / 100 HOLD
Tech 40.0 Fund 54.0 Flow 72.0 Mom 45.0
OABI NASDAQ
OmniAb, Inc. Common Stock
Services-Commercial Physical & Biological Research
$4.66
-7.36% 1D
Market Cap $733.7M
1M Return -2.51%
1Y Return +182.42%
Forward P/E N/M
Unified AI Score
45.5 / 100 HOLD
Tech 15.0 Fund 40.0 Flow 58.0 Mom 40.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: LCTX -54.86% OABI +182.42% Spread: +237.28 pp (OABI Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period LCTX Revenue OABI Revenue LCTX Op. Margin OABI Op. Margin Margin Edge
FY2018 $0M N/A -837.9% N/A LCTX
FY2019 $0M N/A -1106.0% N/A LCTX
FY2020 $0M N/A -1448.4% N/A LCTX
FY2021 $0M $30M -1133.6% -102.5% OABI
FY2022 $10M $60M -153.2% -45.1% OABI
FY2023 $10M $30M -276.5% -203.2% OABI
FY2024 $10M $30M -226.1% -282.3% LCTX
FY2025 $10M $20M -251.6% -369.5% LCTX

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: LCTX (5) vs OABI (5)
Institutional Metric LCTX OABI Criterion Row Winner
Market Capitalization Scale $207.4M $733.7M Larger Scale OABI
Trailing P/E Ratio Valuation 30.7x N/M Lower Multiple LCTX
Forward P/E Ratio Valuation 30.7x N/M Lower Multiple LCTX
Revenue Growth (YoY) Growth -61.0% +78.3% Higher Growth OABI
Operating Margin (TTM) Profitability -280.3% -92.9% Higher Margin OABI
Net Profit Margin Profitability 16.2% -108.1% Higher Margin LCTX
Return on Equity (ROE) Capital Efficiency 4.3% -16.5% Higher ROE LCTX
52-Week Range Position Momentum 0% ($1โ€“$2) 81% ($1โ€“$5) Stronger Trend OABI
Beta / 30D Volatility Risk Regime 1.39ฮฒ ยท 79% Vol 1.24ฮฒ ยท 60% Vol Lower Realized Risk OABI
Unified Institutional Score Composite Signal 54.9 / 100 (HOLD) 45.5 / 100 (HOLD) Higher Composite LCTX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full LCTX vs OABI Buy Guide
LCTX BREAKDOWN
7d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile <1st %ile
IV Regime Compressed (<25th %ile)
Live LCTX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
OABI CONSOLIDATION
17d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 14th %ile
IV Regime Compressed (<25th %ile)
Live OABI Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither LCTX nor OABI registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.